Detalhe da pesquisa
1.
Effectiveness and safety of empagliflozin: final results from the EMPRISE study.
Diabetologia
; 67(7): 1328-1342, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38509341
2.
Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study.
Cardiovasc Diabetol
; 23(1): 57, 2024 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38331813
3.
Stratified analysis in comparative effectiveness studies that emulate randomized trials.
Pharmacoepidemiol Drug Saf
; 33(1): e5716, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37876341
4.
Evaluating Confounding Control in Estimations of Influenza Antiviral Effectiveness in Electronic Health Plan Data.
Am J Epidemiol
; 191(5): 908-920, 2022 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35106530
5.
Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
Ann Intern Med
; 174(11): 1528-1541, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34570599
6.
Counterpoint: Keeping the Demons at Bay When Handling Time-Varying Exposures-Beyond Avoiding Immortal Person-Time.
Am J Epidemiol
; 188(6): 1016-1022, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31155642
7.
Renin-Angiotensin-Aldosterone System-based Antihypertensive Agents and the Risk of Colorectal Cancer Among Medicare Beneficiaries.
Epidemiology
; 30(6): 867-875, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31348009
8.
Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study.
Cardiovasc Diabetol
; 23(1): 103, 2024 Mar 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38500096
9.
Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
Ann Intern Med
; 175(1): W4, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35038405
10.
Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
Ann Intern Med
; 175(1): W4-W5, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35038404
11.
Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors.
Eur J Clin Pharmacol
; 72(8): 1013-23, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27165664
12.
Risk of Severe Hypoglycemia With Newer Second-line Glucose-lowering Medications in Older Adults With Type 2 Diabetes Stratified by Known Indicators of Hypoglycemia Risk.
J Gerontol A Biol Sci Med Sci
; 78(12): 2426-2434, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36866496
13.
Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure.
J Am Heart Assoc
; 11(4): e022376, 2022 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35132865
14.
Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.
JAMA Netw Open
; 5(10): e2237606, 2022 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36264574